0001062993-23-020922.txt : 20231115 0001062993-23-020922.hdr.sgml : 20231115 20231115164144 ACCESSION NUMBER: 0001062993-23-020922 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231113 FILED AS OF DATE: 20231115 DATE AS OF CHANGE: 20231115 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Singer Michael CENTRAL INDEX KEY: 0002000122 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37798 FILM NUMBER: 231411139 MAIL ADDRESS: STREET 1: C/O CARTESIAN THERAPEUTICS, INC. STREET 2: 704 QUINCE ORCHARD RD CITY: GAITHERSBURG STATE: MD ZIP: 20878 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cartesian Therapeutics, Inc. CENTRAL INDEX KEY: 0001453687 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 65 GROVE STREET CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-923-1400 MAIL ADDRESS: STREET 1: 65 GROVE STREET CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: SELECTA BIOSCIENCES INC DATE OF NAME CHANGE: 20090109 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0508 4 2023-11-13 0001453687 Cartesian Therapeutics, Inc. RNAC 0002000122 Singer Michael C/O CARTESIAN THERAPEUTICS, INC. 65 GROVE STREET WATERTOWN MA 02472 1 0 1 0 0 Common Stock 2023-11-13 4 A 0 110123 0 A 110123 D Common Stock 2023-11-13 4 J 0 197663 0 A 197663 I by trust Common Stock 2023-11-13 4 J 0 29212 0 A 29212 I by trust Common Stock 2023-11-13 4 J 0 3670 0 A 3670 I by trust Common Stock 2023-11-13 4 J 0 49555 0 A 49555 I as custodian Common Stock 2023-11-13 4 J 0 49555 0 A 49555 I as custodian Common Stock 2023-11-13 4 J 0 7616 0 A 7616 I by spouse Series A Non-Voting Convertible Preferred Stock 2023-11-13 4 A 0 6304.559 A Common Stock 6304559 6304.559 D Series A Non-Voting Convertible Preferred Stock 2023-11-13 4 J 0 11316.263 A Common Stock 11316263 11316.263 I by trust Series A Non-Voting Convertible Preferred Stock 2023-11-13 4 J 0 1672.389 A Common Stock 1672389 1672.389 I by trust Series A Non-Voting Convertible Preferred Stock 2023-11-13 4 J 0 210.152 A Common Stock 210152 210.152 I by trust Series A Non-Voting Convertible Preferred Stock 2023-11-13 4 J 0 2837.052 A Common Stock 2837052 2837.052 I as custodian Series A Non-Voting Convertible Preferred Stock 2023-11-13 4 J 0 2837.052 A Common Stock 2837052 2837.052 I as custodian Series A Non-Voting Convertible Preferred Stock 2023-11-13 4 J 0 436.066 A Common Stock 436066 436.066 I by spouse On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger. Shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse is a trustee of the trust. Shares are held in a trust for which the reporting person is a beneficiary. The reporting person is a trustee of the trust. Shares are held in a trust for which the reporting person is a beneficiary. The reporting person's spouse is a trustee of the trust. The shares are held for LS, the child of the reporting person, through a custodial account established pursuant to the Uniform Transfer to Minors Act ("UTMA") for which the reporting person serves as custodian. The shares are held for SS, the child of the reporting person, through a custodial account established pursuant to the UTMA for which the reporting person serves as custodian. Shares are held by the reporting person's spouse. Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. /s/ Michael Singer 2023-11-15